AlphaCore Capital LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

AlphaCore Capital LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFEGet Rating) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 16,522 shares of the biopharmaceutical company’s stock, valued at approximately $855,000. Pfizer makes up 0.3% of AlphaCore Capital LLC’s investment portfolio, making the stock its 28th largest position.

Other institutional investors have also modified their holdings of the company. Bessemer Group Inc. increased its position in shares of Pfizer by 16.8% during the 4th quarter. Bessemer Group Inc. now owns 200,669 shares of the biopharmaceutical company’s stock worth $11,849,000 after purchasing an additional 28,928 shares during the last quarter. Bordeaux Wealth Advisors LLC increased its holdings in shares of Pfizer by 8.8% during the 4th quarter. Bordeaux Wealth Advisors LLC now owns 20,502 shares of the biopharmaceutical company’s stock worth $1,211,000 after acquiring an additional 1,665 shares during the last quarter. Krilogy Financial LLC grew its holdings in Pfizer by 27.7% in the 4th quarter. Krilogy Financial LLC now owns 15,531 shares of the biopharmaceutical company’s stock valued at $917,000 after buying an additional 3,367 shares in the last quarter. Vantage Financial Partners Ltd. Inc. lifted its position in shares of Pfizer by 5.2% during the 4th quarter. Vantage Financial Partners Ltd. Inc. now owns 13,200 shares of the biopharmaceutical company’s stock valued at $779,000 after acquiring an additional 650 shares during the period. Finally, Baker Ellis Asset Management LLC lifted its position in shares of Pfizer by 3.9% during the 4th quarter. Baker Ellis Asset Management LLC now owns 11,182 shares of the biopharmaceutical company’s stock worth $660,000 after buying an additional 416 shares during the last quarter. Institutional investors own 66.50% of the company’s stock.

Pfizer Trading Down 0.7 %

NYSE:PFE opened at $51.95 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.39 and a quick ratio of 1.13. The firm has a market capitalization of $291.49 billion, a price-to-earnings ratio of 11.92, a price-to-earnings-growth ratio of 0.62 and a beta of 0.73. Pfizer Inc. has a one year low of $40.94 and a one year high of $61.71. The business has a fifty day moving average price of $51.50 and a 200-day moving average price of $51.37.

Pfizer (NYSE:PFEGet Rating) last issued its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.66 by ($0.04). The business had revenue of $25.66 billion during the quarter, compared to analysts’ expectations of $24.73 billion. Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The company’s quarterly revenue was up 76.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.93 EPS. Sell-side analysts forecast that Pfizer Inc. will post 6.67 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Wednesday, June 29th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.08%. The ex-dividend date is Thursday, July 28th. Pfizer’s payout ratio is 36.70%.

Insider Activity at Pfizer

In related news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the stock in a transaction dated Thursday, May 12th. The shares were sold at an average price of $50.00, for a total value of $1,645,400.00. Following the completion of the transaction, the executive vice president now owns 38,146 shares of the company’s stock, valued at approximately $1,907,300. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Pfizer news, SVP Jennifer B. Damico sold 4,218 shares of the firm’s stock in a transaction dated Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total value of $227,603.28. Following the completion of the sale, the senior vice president now owns 10,846 shares of the company’s stock, valued at $585,250.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of Pfizer stock in a transaction that occurred on Thursday, May 12th. The shares were sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the sale, the executive vice president now directly owns 38,146 shares of the company’s stock, valued at approximately $1,907,300. The disclosure for this sale can be found here. In the last quarter, insiders sold 41,126 shares of company stock valued at $2,075,003. Insiders own 0.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PFE. JPMorgan Chase & Co. set a $57.00 target price on Pfizer in a report on Tuesday, June 28th. Berenberg Bank set a $50.00 price target on Pfizer in a research note on Friday, May 27th. Morgan Stanley decreased their target price on Pfizer from $52.00 to $49.00 and set an “equal weight” rating for the company in a research note on Friday, July 8th. Barclays set a $52.00 price target on Pfizer in a report on Thursday, July 7th. Finally, The Goldman Sachs Group set a $51.00 price target on Pfizer in a report on Wednesday, July 13th. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $56.95.

About Pfizer

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.